AIMS-2-TRIALS - Autism Research For Europe
  • Home
  • About Us
    • About Us
    • FAQs
    • Team
      • Autism-Europe
      • University of Basel
      • Birkbeck, University of London
      • University of Bristol
      • University of Cambridge
      • Central Institute of Mental Health, Mannheim
      • Clinical Foundation for Biomedical Research, Barcelona
      • University of Coimbra
      • Trinity College Dublin
      • European College of Neuropsychopharmacology
      • University of Edinburgh
      • French Alternative Energies and Atomic Energy Commission
      • French National Institute of Health and Medical Research
      • Ghent University
      • University of Glasgow
      • Goethe University Frankfurt
      • University Medical Centre Göttingen
      • University of Groningen
      • Health Services of Madrid
      • Institut Pasteur
      • Karolinska Institute
      • King’s College London
      • Technical University Munich
      • University of Newcastle
      • University of Oxford
      • Radboudumc, Nijmegen
      • Public Hospitals of Paris
      • Policlínica Gipuzkoa Foundation
      • University of Salamanca
      • Stellenbosch University
      • Stella Maris Foundation
      • University Hospitals of Tours
      • Ulm University
      • UMC Utrecht
      • Uppsala University
      • ARTTIC
      • BioSci Consulting
      • DEMCON
      • Noldus
      • Starlab
      • Janssen
      • Novartis
      • Roche
      • Teva
      • UCB Biopharma
      • Autism Speaks
      • Autistica
      • Simons Foundation
    • Project Management
    • Communication
    • Funding
    • EU-AIMS
    • Contact Us
  • Autism Community
    • Autism Community
    • Autism Representatives
    • How You Benefit
    • Language
    • Resources
  • Our Research
    • Our Research
    • Biomarkers
    • Testing Medicines
    • Outcome Measures
    • Beyond Medicines
    • Data Analysis
    • Autism Policies
    • Clinical Trials Network
    • Ethics
    • How to get involved
  • News
    • News
    • Publications
Select Page
  • Contacts
  • Imprint & Disclaimer
  • Privacy Policy
  • Copyright
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.

Contact    Imprint & Disclaimer   Privacy Policy    Copyright    Twitter    LinkeIn

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.
Any views expressed are those of the author(s) and not necessarily those of the funders.

IMI
EU
SFARI
Autistica
AUTISM SPEAKS
Published: October 16, 2018
AIMS-2-TRIALS